| [1] |
KÖHLER G,MILSTEIN C. Continuous cultures of fused cells secreting antibody of predefined specificity[J]. Nature,1975,256(5517):495-497.
|
| [2] |
THORPE S J,TURNER C,HEATH A,et al.Clonal analysis of a human antimouse antibody (HAMA) response[J]. Scand J Immunol,2003,57(1):85-92.
|
| [3] |
BUSS N A,HENDERSON S J,MCFARLANE M,et al.Monoclonal antibody therapeutics:history and future[J]. Curr Opin Pharmacol,2012,12(5):615-622.
|
| [4] |
NELSON A L,DHIMOLEA E,REICHERT J M.Development trends for human monoclonal antibody therapeutics[J]. Nat Rev Drug Discov,2010,9(10):767-774.
|
| [5] |
ECKER D M,JONES S D,LEVINE H L.The therapeutic monoclonal antibody market[J]. MAbs,2015,7(1):9-14.
|
| [6] |
LI P,ZHENG Y,CHEN X.Drugs for autoimmune inflammatory diseases:from small molecule compounds to anti-TNF biologics[J]. Front Pharmacol,2017,8:460.
|
| [7] |
REDDY V,CAMBRIDGE G,ISENBERG D A,et al.Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus[J]. Arthritis Rheumatol,2015,67(8):2046-2055.
|
| [8] |
RIZZIERI D.Zevalin(®) (ibritumomab tiuxetan):after more than a decade of treatment experience,what have we learned?[J]. Crit Rev Oncol Hematol,2016,105:5-17.
|
| [9] |
DHILLON S.Obinutuzumab:a review in rituximab-refractory or-relapsed follicular lymphoma[J]. Targ Oncol,2017,12:255-262.
|
| [10] |
MONTALBAN X,HAUSER S L,KAPPOS L,et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis[J]. N Engl J Med,2017,376(3):209-220.
|
| [11] |
NAGORSEN D,KUFER P,BAEUERLE P A,et al.Blinatumomab:a historical perspective[J]. Pharmacol Ther,2012,136(3):334-342.
|
| [12] |
SANFORD M.Blinatumomab:first global approval[J]. Drugs,2015,75(3):321-327.
|
| [13] |
BALDASSARI L E,ROSE J W.Daclizumab:development,clinical trials,and practical aspects of use in multiple sclerosis[J]. Neurotherapeutics,2017,14(4):842-858.
|
| [14] |
RECH A J,MICK R,MARTIN S,et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients[J]. Sci Transl Med,2012,4(134):134ra162.
|
| [15] |
LONIAL S,WEISS B M,USMANI S Z,et al.Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS):an open-label,randomised,phase 2 trial[J]. Lancet,2016,387(10027):1551-1560.
|
| [16] |
TEBBUTT N,PEDERSEN M W,JOHNS T G.Targeting the ERBB family in cancer:couples therapy[J]. Nat Rev Cancer,2013,13(9):663-673.
|
| [17] |
BOLAND W K,BEBB G.Nimotuzumab:a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity[J]. Expert Opin Biol Ther,2009,9(9):1199-1206.
|
| [18] |
LIU Z G,ZHAO Y,TANG J,et al.Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma:a retrospective analysis[J]. Oncotarget,2016,7(17):24429-24435.
|
| [19] |
BONNER J A,HARARI P M,GIRALT J,et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med,2006,354(6):567-578.
|
| [20] |
KEATING G M.Panitumumab:a review of its use in metastatic colorectal cancer[J]. Drugs,2010,70(8):1059-1078.
|
| [21] |
ROMOND E H,PEREZ E A,BRYANT J,et al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J]. N Engl J Med,2005,353(16):1673-1684.
|
| [22] |
JUNTTILA T T,LI G,PARSONS K,et al.Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer[J]. Breast Cancer Res Treat,2011,128(2):347-356.
|
| [23] |
FRIEND R,BHUTANI M,VOORHEES P M,et al.Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma[J]. Drug Des Devel Ther,2017,11:893-900.
|
| [24] |
TAI Y T,DILLON M,SONG W,et al.Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu[J]. Blood,2008,112(4):1329-1337.
|
| [25] |
LONIAL S,DIMOPOULOS M,PALUMBO A,et al.Elotuzumab therapy for relapsed or refractory multiple myeloma[J]. N Engl J Med,2015,373(7):621-631.
|
| [26] |
BROWN E R,CHARLES K A,HOARE S A,et al.A clinical study assessing the tolerability and biological effects of infliximab,a TNF-alpha inhibitor,in patients with advanced cancer[J]. Ann Oncol,2008,19(7):1340-1346.
|
| [27] |
LE D T,DURHAM J N,SMITH K N,et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science,2017,357(6349):409-413.
|
| [28] |
TOPALIAN S L,TAUBE J M,ANDERS R A,et al.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer,2016,16(5):275-287.
|
| [29] |
ISHIDA Y,AGATA Y,SHIBAHARA K,et al.Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily,upon programmed cell death[J]. EMBO J,1992,11(11):3887-3895.
|
| [30] |
IBRAHIM R,STEWART R,SHALABI A.PD-L1 blockade for cancer treatment:MEDI4736[J]. Semin Oncol,2015,42(3):474-483.
|
| [31] |
KWOK G,YAU T C,CHIU J W,et al.Pembrolizumab (Keytruda)[J]. Hum Vaccin Immunother,2016,12(11):2777-2789.
|
| [32] |
EL-KHOUEIRY A B,SANGRO B,YAU T,et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J]. Lancet,2017,389(10088):2492-2502.
|
| [33] |
ROUTY B,LE CHATELIER E,DEROSA L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science,2018,359(6371):91-97.
|
| [34] |
WARTEWIG T,KURGYIS Z,KEPPLER S,et al.Erratum:PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis[J]. Nature,2018,553(7687):238.
|
| [35] |
BATRA J,RATHORE A S.Glycosylation of monoclonal antibody products:current status and future prospects[J]. Biotechnol Prog,2016,32(5):1091-1102.
|
| [36] |
YI C H,RUAN C P,WANG H,et al.Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro[J]. Acta Pharmacol Sin,2014,35(11):1439-1446.
|
